KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Non-Current Deffered Revenue (2017 - 2025)

Moderna (MRNA) has disclosed Non-Current Deffered Revenue for 9 consecutive years, with $153.0 million as the latest value for Q4 2025.

  • Quarterly Non-Current Deffered Revenue rose 163.79% to $153.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $153.0 million through Dec 2025, up 163.79% year-over-year, with the annual reading at $153.0 million for FY2025, 163.79% up from the prior year.
  • Non-Current Deffered Revenue for Q4 2025 was $153.0 million at Moderna, down from $157.0 million in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $692.0 million in Q2 2023, with the low at $58.0 million in Q1 2024.
  • Average Non-Current Deffered Revenue over 5 years is $276.8 million, with a median of $170.5 million recorded in 2021.
  • The sharpest move saw Non-Current Deffered Revenue surged 247.46% in 2021, then crashed 91.38% in 2024.
  • Over 5 years, Non-Current Deffered Revenue stood at $615.0 million in 2021, then grew by 9.43% to $673.0 million in 2022, then tumbled by 87.67% to $83.0 million in 2023, then tumbled by 30.12% to $58.0 million in 2024, then surged by 163.79% to $153.0 million in 2025.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $153.0 million, $157.0 million, and $65.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.